206 related articles for article (PubMed ID: 2939797)
1. Antimicrobial activity of ciprofloxacin against Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus determined by the killing curve method: antibiotic comparisons and synergistic interactions.
Chalkley LJ; Koornhof HJ
Antimicrob Agents Chemother; 1985 Aug; 28(2):331-42. PubMed ID: 2939797
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.
Stamm JM; Hanson CW; Chu DT; Bailer R; Vojtko C; Fernandes PB
Antimicrob Agents Chemother; 1986 Feb; 29(2):193-200. PubMed ID: 3087274
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the in vitro and in vivo activity of ciprofloxacin measured against current standards of therapy.
Zeiler HJ; Metzger KG; Schacht P; Grohe K
Drugs Exp Clin Res; 1985; 11(5):343-50. PubMed ID: 2941263
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ciprofloxacin with azlocillin plus tobramycin in the therapy of experimental Pseudomonas aeruginosa endocarditis.
Strunk RW; Gratz JC; Maserati R; Scheld WM
Antimicrob Agents Chemother; 1985 Sep; 28(3):428-32. PubMed ID: 2934021
[TBL] [Abstract][Full Text] [Related]
5. Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.
Chin NX; Jules K; Neu HC
Eur J Clin Microbiol; 1986 Feb; 5(1):23-8. PubMed ID: 2938945
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of ciprofloxacin alone and in combination with azlocillin in an in-vitro capillary model.
Zinner SH; Dudley MN
J Antimicrob Chemother; 1986 Nov; 18 Suppl D():49-54. PubMed ID: 3100491
[TBL] [Abstract][Full Text] [Related]
7. Time-survival studies for quantifying effects of azlocillin and tobramycin on Pseudomonas aeruginosa.
McFarland MM; Scott EM; Li Wan Po A
Antimicrob Agents Chemother; 1994 Jun; 38(6):1271-6. PubMed ID: 8092825
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity of ciprofloxacin in serum and urine against Escherichia coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus aureus and Streptococcus faecalis.
Lagast H; Husson M; Klastersky J
J Antimicrob Chemother; 1985 Sep; 16(3):341-7. PubMed ID: 2932416
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ciprofloxacin in combination with ceftazidime, aztreonam, and azlocillin against multiresistant isolates of Pseudomonas aeruginosa.
Bustamante CI; Wharton RC; Wade JC
Antimicrob Agents Chemother; 1990 Sep; 34(9):1814-5. PubMed ID: 2126693
[TBL] [Abstract][Full Text] [Related]
10. Comparative efficacy of ciprofloxacin, azlocillin, and tobramycin alone and in combination in experimental Pseudomonas sepsis.
Johnson M; Miniter P; Andriole VT
J Infect Dis; 1987 Apr; 155(4):783-8. PubMed ID: 3102631
[TBL] [Abstract][Full Text] [Related]
11. Serum bactericidal activity from intravenous ciprofloxacin and azlocillin given alone and in combination to healthy subjects.
Orlando PL; Barriere SL; Hindler JA; Frost RW
Diagn Microbiol Infect Dis; 1990; 13(2):93-7. PubMed ID: 2114954
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.
Moody JA; Gerding DN; Peterson LR
Am J Med; 1987 Apr; 82(4A):44-54. PubMed ID: 3107380
[TBL] [Abstract][Full Text] [Related]
13. Influence of ciprofloxacin on the ultrastructure of gram-negative and gram-positive bacteria.
Voigt WH; Zeiler HJ
Arzneimittelforschung; 1985; 35(10):1600-3. PubMed ID: 2934069
[TBL] [Abstract][Full Text] [Related]
14. [Synergism of ciprofloxacin with beta-lactam antibiotics, gentamicin, minocycline and pipemidic acid].
Dickgiesser N; in der Stroth S; Wundt W
Infection; 1986; 14(2):82-5. PubMed ID: 2940188
[TBL] [Abstract][Full Text] [Related]
15. Determination of synergy by two methods with eight antimicrobial combinations against tobramycin-susceptible and tobramycin-resistant strains of Pseudomonas.
Chan EL; Zabransky RJ
Diagn Microbiol Infect Dis; 1987 Feb; 6(2):157-64. PubMed ID: 3102156
[TBL] [Abstract][Full Text] [Related]
16. Influence of pH and human urine on the antibacterial activity of ciprofloxacin, norfloxacin and ofloxacin.
Zeiler HJ
Drugs Exp Clin Res; 1985; 11(5):335-8. PubMed ID: 2941261
[TBL] [Abstract][Full Text] [Related]
17. [Synergistic activity between ticarcillin, azlocillin, cefsulodin, ceftazidime and tobramycin or amikacin against Pseudomonas aeruginosa (author's transl)].
Petit JC; Richard G; Burghoffer B; Daguet GL
Pathol Biol (Paris); 1982 Jun; 30(6):426-31. PubMed ID: 6810286
[TBL] [Abstract][Full Text] [Related]
18. Minimum inhibitory and bactericidal concentrations of 44 antimicrobial agents against three standard control strains in broth with and without human serum.
Reimer LG; Stratton CW; Reller LB
Antimicrob Agents Chemother; 1981 Jun; 19(6):1050-5. PubMed ID: 6791584
[TBL] [Abstract][Full Text] [Related]
19. The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo.
Amison RT; Faure ME; O'Shaughnessy BG; Bruce KD; Hu Y; Coates A; Page CP
Pulm Pharmacol Ther; 2020 Apr; 61():101884. PubMed ID: 31887372
[TBL] [Abstract][Full Text] [Related]
20. In-vitro study of the activity of ciprofloxacin alone and in combination against strains of Pseudomonas aeruginosa with multiple antibiotic resistance.
Davies GS; Cohen J
J Antimicrob Chemother; 1985 Dec; 16(6):713-7. PubMed ID: 2936706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
